Dasatinib preferentially induces apoptosis by inhibiting Lyn kinase in nilotinib-resistant chronic myeloid leukemia cell line
2011

Dasatinib's Effect on Nilotinib-Resistant CML Cells

Sample size: 23 publication Evidence: moderate

Author Information

Author(s): Okabe Seiichi, Tauchi Tetsuzo, Tanaka Yuko, Ohyashiki Kazuma

Primary Institution: Tokyo Medical University

Hypothesis

Can dasatinib induce apoptosis in nilotinib-resistant chronic myeloid leukemia cells by inhibiting Lyn kinase?

Conclusion

Dasatinib effectively induces apoptosis in nilotinib-resistant CML cells by inhibiting Lyn kinase activity.

Supporting Evidence

  • Dasatinib reduced the cell growth of K562NR and significantly induced apoptosis.
  • The IC50 of dasatinib is 5 nM.
  • K562NR cells underwent increased phosphorylation of Src family kinases including Lyn.
  • Phosphorylation of SFK was reduced after 24-hrs dasatinib treatment in a dose-dependent manner.

Takeaway

This study shows that a medicine called dasatinib can help kill cancer cells that don't respond to another medicine called nilotinib.

Methodology

The study established a nilotinib-resistant cell line and evaluated the resistance to nilotinib and the efficacy of dasatinib.

Limitations

The study was conducted in vitro and may not fully represent in vivo conditions.

Participant Demographics

Patients included in the study had chronic myeloid leukemia and were resistant to imatinib and nilotinib.

Digital Object Identifier (DOI)

10.1186/1756-8722-4-32

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication